• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

News

Article

March 19, 2025

FDA Grants Orphan Drug Designation to Radiprodil for GRIN-Related Neurodevelopmental Disorder

Author(s):

Luke Halpern, Assistant Editor

Key Takeaways

  • Radiprodil targets N-methyl-D-aspartate receptor subtype 2B and has received FDA orphan drug designation for GRIN-related NDD.
  • The phase 1b Honeycomb trial demonstrated radiprodil's tolerability and efficacy, with an 86% median reduction in countable motor seizures.
  • A phase 3 trial in 2025 will include patients with GRIN mutations to further evaluate radiprodil's clinical potential.
  • GRIN-related NDDs are rare pediatric disorders with symptoms like intellectual disabilities, epilepsy, and developmental delays.
SHOW MORE

Patients with a disorder from this family of neurodevelopmental conditions face a lack of approved treatment options, making radiprodil poised to transform the treatment paradigm.

The FDA has granted orphan drug designation (ODD) to radiprodil (GRIN Therapeutics) for the treatment of GRIN-related neurodevelopmental disorder (NDD). Designed as a negative allosteric modulator that selectively targets N-methyl-D-aspartate receptor subtype 2B, radiprodil is slated to be investigated in a pivotal phase 3 trial in 2025 for the treatment of GRIN-related NDD with gain-of-function (GoF) mutations.1

Vibrant Neural Connections and Brain Activity

Image Credit: © LemonellArt - stock.adobe.com

With ODD, radiprodil can benefit from tailored FDA support towards research and development that could eventually lead to full regulatory approval, which would provide a treatment for the thousands of patients that live with this rare disorder. In addition, radiprodil was granted breakthrough disease designation in February 2025 by the FDA for the treatment of seizures associated with GRIN-related NDD in patients with GoF mutations. The 2 designations are poised to propel raidprodil towards full FDA approval in the future.1,2

At the American Epilepsy Society (AES) Annual Meeting in December 2024, GRIN Therapeutics presented data from the global, open-label, phase 1b Honeycomb trial that investigated the tolerability, safety, pharmacokinetics, and efficacy of radiprodil. In the trial, radiprodil was generally well-tolerated among patients, with the most common observed adverse events associated with underlying disease symptoms or infections. Among patients in the qualifying seizure cohort, there was a median reduction of 86% in countable motor seizures (CMS) frequency compared with baseline, a consistent observation observed across all GRIN genotypes.3

Furthermore, throughout the trial period, 71% of patients treated with radiprodil had a greater than 50% in CMS, while 6 of the 7 participants were seizure-free during at least 80% of days throughout the 8-week maintenance period. Importantly, the study investigators observed signs of a favorable effect on clinical outcomes regardless of the occurrence of seizures, as measured by 2 scores: Clinician and Caregiver Global Impressions of Change and the Aberrant Behavior Checklist—Community.3

The design of the phase 3 trial, a randomized, double-blind, placebo-controlled study, is set to include 2 cohorts of patients with confirmed GRIN mutations. These include GRIN1, GRIN2A, GRIN2B, and GRIN2D genes. The investigators intend to have a cohort of enrolled patients who have experienced qualifying CMS, and another cohort of patients without such seizures. Results from this pivotal trial will aid investigators in determining the next steps in radiprodil’s clinical development.3

“We are making rapid progress in our efforts to bring a first-ever treatment for GRIN-related neurodevelopmental disorder to patients,” Michael A Panzara, MD, MPH, chief medical officer at GRIN Therapeutics, said in a news release. “Supported by our promising clinical data, the FDA’s decision to grant orphan drug designation to radiprodil is the latest milestone in that effort.”1

GRIN-related NDD comprises rare, genetically defined pediatric NDDs caused by mutations in GRIN genes. Diagnosis of such a disorder is typically not confirmed until a child is aged 2 years or later, when a child can be observed failing to reach developmental milestones. Signs of GRIN-related NDD include the potential of intellectual disabilities, developmental delay, epilepsy, muscular hypotonia, movement disorders, spasticity, and feeding and behavioral difficulties.3

Given the lack of approved therapies for GRIN-related NDD, radiprodil’s clinical development should be closely watched by treatment providers and patients alike.

REFERENCES
1. GRIN Therapeutics. GRIN Therapeutics receives FDA orphan drug designation for radiprodil for the treatment of GRIN-related neurodevelopmental disorder. News Release. Released March 17, 2025. Accessed March 18, 2025. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://neurvati.com/wp-content/uploads/Radiprodil-Orphan-Drug-Announcement-Release-FINAL.pdf
2. GRIN Therapeutics. GRIN Therapeutics receives FDA breakthrough therapy designation for radiprodil. News Release. Released February 25, 2025. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://neurvati.com/wp-content/uploads/Radiprodil-Breakthrough-Therapy-Designation-Final.pdf
3. GRIN Therapeutics. GRIN Therapeutics presents data from Honeycomb trial of radiprodil at the American Epilepsy Society Annual Meeting. News Release. Released December 9, 2024. Accessed March 18, 2025. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://neurvati.com/wp-content/uploads/AES-2024-Press-Release-Final-PDF.pdf

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Menoapuse spelled with wooden blocks -- Image credit: loran4a | stock.adobe.com
Related Content
Advertisement
Chronic kidney disease (CKD) -- Image credit: Kiattisak | stock.adobe.com
June 12th 2025

Finerenone and Empagliflozin Outperform Either Treatment Alone in Patients With CKD

Gillian McGovern, Associate Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
FDA Approves Tablet Formulation of Zanubrutinib for All Indications
June 11th 2025

FDA Approves Tablet Formulation of Zanubrutinib for All Indications

Luke Halpern, Assistant Editor
Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment
September 26th 2024

Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment

Image credit: David A Litman | stock.adobe.com
June 11th 2025

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Gillian McGovern, Associate Editor
Paper puzzle of brain representing dementia -- Image credit: SewcreamStudio | stock.adobe.com
June 11th 2025

Study Finds Depression May Increase Risk of Developing Dementia

Gillian McGovern, Associate Editor
Related Content
Advertisement
Chronic kidney disease (CKD) -- Image credit: Kiattisak | stock.adobe.com
June 12th 2025

Finerenone and Empagliflozin Outperform Either Treatment Alone in Patients With CKD

Gillian McGovern, Associate Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
FDA Approves Tablet Formulation of Zanubrutinib for All Indications
June 11th 2025

FDA Approves Tablet Formulation of Zanubrutinib for All Indications

Luke Halpern, Assistant Editor
Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment
September 26th 2024

Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment

Image credit: David A Litman | stock.adobe.com
June 11th 2025

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Gillian McGovern, Associate Editor
Paper puzzle of brain representing dementia -- Image credit: SewcreamStudio | stock.adobe.com
June 11th 2025

Study Finds Depression May Increase Risk of Developing Dementia

Gillian McGovern, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.